drugset / Trial / NCT03198026
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
Phase 2
Active not recruiting
30 enrolled
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Genentech, Inc. · collabPharmacyclics LLC. · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well obinutuzumab and ibrutinib work as front line therapy in treating patients with indolent non-Hodgkin's lymphoma. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab and ibrutinib may work better in treating patients with non-Hodgkin's lymphomas.
Timeline
- Start
- 2018-02-20
- Primary completion
- 2026-09-11
- Completion
- 2032-02-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | — | Oral |
| Subject | Obinutuzumab | Monoclonal antibody | — | Intravenous |